Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

QBS10072S

Small molecule · Cytotoxic, directed at LAT1 (SLC7A5)

Phase 2 Most advanced trial
1 Registered trials

What is QBS10072S?

QBS10072S is a blood-brain-barrier penetrative small molecule composed of a cytotoxic chemotherapeutic domain linked to a LAT1 substrate. It binds LAT1 on the blood-brain barrier and LAT1-expressing tumor cells, enters the brain, and induces DNA damage, cell cycle arrest, and apoptosis. It is studied in glioblastoma multiforme.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
LAT1 (SLC7A5), DNA (secondary target)
Mechanism
Cytotoxic, directed at LAT1 (SLC7A5)
Pathways
cell cycle arrest, apoptosis
Therapy area
Oncology
In trials of
PBYI
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02977780 Phase 2 Glioblastoma Recruiting PBYI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Other drugs acting on SLC7A5

Iodine I 131 IPA Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.